Pharma and the mHealth Revolution - Engaging with Mobile-Enabled Physicians and HCPs
It’s time to click on this.
The media’s dubbed them ‘a doctor in your pocket’ and ‘health care helpers’. Yet despite the explosion of mobile apps in other industries, pharma has generally been slow to exploit the possibilities they represent. What are the hurdles facing the industry and who are the leaders overcoming them? How can companies develop a mHealth approach that both addresses end-user needs and key messaging? What does pharma need to know about regulatory and legal hurdles?
Concisely written and expertly researched, this FirstWord Dossier report succinctly addresses the issues surrounding the emerging mHealth industry—and finds the answers.
Report Overview
Offering a compelling case for pharma to firmly establish its voice in mHealth, the report contains detailed insight into the opportunities app development represents. Encompassing the full range of questions demanded by the industry, the report includes expert insight from both those in pharma currently working ahead of the curve and mHealth developers themselves.
Whether your company is looking to expand into mHealth apps or seeking sound advice on a way forward, Pharma and the mHealth Revolution - engaging with mobile-enabled physicians and HCPs has the answers.
Key Report Features
“The business case for pharma to engage in mHealth makes a lot of sense. But pharma has been quite slow to really embrace things in mobile health in a strategic or systematic way.” Dr. Patricia Mechael, executive director, mHealth Alliance
“There is substantial opportunity for pharmaceutical companies to be involved; it’s just that they have to walk that fine line between providing a service to the patient population and having what they’re doing viewed as just a kind of marketing. As soon as it gets perceived as the latter, all the alarm bells will go off.” Dr. Satish Misra, managing editor, iMedicalApps
Who Should Read This Report?
The media’s dubbed them ‘a doctor in your pocket’ and ‘health care helpers’. Yet despite the explosion of mobile apps in other industries, pharma has generally been slow to exploit the possibilities they represent. What are the hurdles facing the industry and who are the leaders overcoming them? How can companies develop a mHealth approach that both addresses end-user needs and key messaging? What does pharma need to know about regulatory and legal hurdles?
Concisely written and expertly researched, this FirstWord Dossier report succinctly addresses the issues surrounding the emerging mHealth industry—and finds the answers.
Report Overview
Offering a compelling case for pharma to firmly establish its voice in mHealth, the report contains detailed insight into the opportunities app development represents. Encompassing the full range of questions demanded by the industry, the report includes expert insight from both those in pharma currently working ahead of the curve and mHealth developers themselves.
Whether your company is looking to expand into mHealth apps or seeking sound advice on a way forward, Pharma and the mHealth Revolution - engaging with mobile-enabled physicians and HCPs has the answers.
Key Report Features
- Convincing arguments for further involvement from pharma in developing mHealth apps for healthcare providers
- Detailed insight into five major pharma mHealth projects
- Methodologies for determining the platforms on which mHealth apps should be launched
- Advice on how to maximise end-user needs to make mHealth products popular with health care professionals
- Insight into navigating legal, regulatory and intellectual property issues
- Solid predictions of future mHealth growth
- Case study of how one major pharma company has evolved its mHealth strategy
- Discover how to develop an mHealth approach that aligns with company goals
- Learn the key lessons of optimising apps and websites for healthcare providers
- Learn how to navigate the main road bumps, including legal, regulatory and intellectual property issues
- Gain insight into what the leaders in the field know and how they’re making mHealth apps work for them
- Get access to detailed case studies from companies such as Eli Lilly, AstraZeneca, Johnson & Johnson, AliveCor and GSK
- When should a pharma company enter the mHealth market?
- What approach should be taken in answering both company strategy and end-user needs?
- What are the main hurdles facing the industry and how can they be overcome?
- What realities do app designers for international markets face?
- How can apps be developed for maximum usage across HCPs?
- What are the guidelines for designing apps for tablet or smartphones?
“The business case for pharma to engage in mHealth makes a lot of sense. But pharma has been quite slow to really embrace things in mobile health in a strategic or systematic way.” Dr. Patricia Mechael, executive director, mHealth Alliance
“There is substantial opportunity for pharmaceutical companies to be involved; it’s just that they have to walk that fine line between providing a service to the patient population and having what they’re doing viewed as just a kind of marketing. As soon as it gets perceived as the latter, all the alarm bells will go off.” Dr. Satish Misra, managing editor, iMedicalApps
Who Should Read This Report?
- Pharma medical affairs directors
- Marketing executives
- Compliance directors and legal teams
- IT managers
- PR firms with interests in the pharmaceutical industry
- Digital marketing agencies
- App and web designers
- Dr. Dave Albert, Co-founder and Chief Medical Officer, AliveCor
- Orion Armon, Partner, Cooley LLP
- Kenneth Bennett, Senior Director, IS Business Partner, Sanofi US division
- Lena Feygin, Managing Director, WeMultiply
- Shwen Gwee, Vice President, Digital Health, Edelman
- Peter Justason, Director, eMarketing, Purdue Pharma
- Duncan Learmouth, Senior Vice President, Developing Countries & Market Access, GlaxoSmithKline
- Jonathan Martin, Director of Education and Awareness Programs, National Marfan Foundation
- Dr. Patricia Mechael, Executive Director, mHealth Alliance
- Brian Meltzer, Executive Director, R&D Innovation, Purdue Pharma
- Dr. Satish Misra, Managing Editor, iMedicalApps and member, Steering Committee, Johns Hopkins Global mHealth Initiative
- Scott Morrison, Vice President, Information Systems, Boehringer Ingelheim
- Judy Wade, ex-CEO, AliveCor
EXECUTIVE SUMMARY
INTRODUCTION
POSSIBILITIES
On the go
Device ownership
Medical practice has changed
Using mHealth devices
Topic diversity
Global diversity
REALITIES
The pioneers
Rules of engagement
Phone or web?
PHARMA’S ROLE IN MHEALTH - FIVE DETAILED EXAMPLES
Eli Lilly: Glucagon mobile app
AstraZeneca: EGFR mutation test
Johnson & Johnson: BlackBag
AliveCor: Heart monitor
GlaxoSmithKline: Mozambique vaccines programme
CASE STUDY
Sanofi’s mHealth strategy
A variety of offerings
The bottom line
UNCERTAINTIES
Regulators weighing options
A Congressional approach
Intellectual property concerns
User hesitancy
WHAT’S AHEAD?
Predicted growth
Emerging technology
Listening to the users
Assuring efficacy
The final requirement: Patience
ACKNOWLEDGEMENTS
INTRODUCTION
POSSIBILITIES
On the go
Device ownership
Medical practice has changed
Using mHealth devices
Topic diversity
Global diversity
REALITIES
The pioneers
Rules of engagement
Phone or web?
PHARMA’S ROLE IN MHEALTH - FIVE DETAILED EXAMPLES
Eli Lilly: Glucagon mobile app
AstraZeneca: EGFR mutation test
Johnson & Johnson: BlackBag
AliveCor: Heart monitor
GlaxoSmithKline: Mozambique vaccines programme
CASE STUDY
Sanofi’s mHealth strategy
A variety of offerings
The bottom line
UNCERTAINTIES
Regulators weighing options
A Congressional approach
Intellectual property concerns
User hesitancy
WHAT’S AHEAD?
Predicted growth
Emerging technology
Listening to the users
Assuring efficacy
The final requirement: Patience
ACKNOWLEDGEMENTS
